Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Evaluating the Clinical Relevance of Necroptosis in Ischemia Reperfusion Injury in Human Lung Transplants.
FY 2022-23
Summary
Lung transplantation (LTx) is the only curative treatment for patients suffering from end-stage lung diseases. Unfortunately, LTx is limited by the low number of donor lungs accepted by the transplant teams. This low utilization results from the lungs’ high susceptibility to injury during the transplant process, which contributes to many lungs being discarded prior to transplantation. Ischemia-reperfusion injury (IRI) in the lung is an inevitable consequence of LTx. IRI is known to promote development of primary graft dysfunction (PGD) – one of the leading causes of patient illness and death after LTx. As a result, there is a critical need for the development of therapeutic avenues to target IRI to improve patient outcome post-transplant. Necroptosis, a form of regulated cell death, has been implicated as a major promoter of IRI in studies done with cells and animals simulating LTx. However, this has not been tested in human LTx cases. We hypothesize that necroptosis plays a critical role in IRI in human LTx and will influence the clinical outcome of patients following LTx. To test this, we will assess biopsies from human donor lungs and the plasma of the recipient patients after LTx for the presence of necroptosis markers. The levels of these markers will then be assessed in relation to the characteristics of the donor patients and the clinical outcome of the recipient patients. Overall, these results will identify the clinical relevance of necroptosis in human LTx and potentially highlight a new avenue for future therapeutics that target IRI; ultimately, increasing the use of donor lungs and improving post-transplant patient outcomes.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
485913
Name
Main Kimberly L
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Evaluating the Clinical Relevance of Necroptosis in Ischemia Reperfusion Injury in Human Lung Transplants.
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cell Death; Human Clinical Samples; Ischemia-Reperfusion Injury; Lung Transplantation; Necroptosis; Primary Graft Dysfunction
Abstract
Lung transplantation (LTx) is the only curative treatment for patients suffering from end-stage lung diseases. Unfortunately, LTx is limited by the low number of donor lungs accepted by the transplant teams. This low utilization results from the lungs’ high susceptibility to injury during the transplant process, which contributes to many lungs being discarded prior to transplantation. Ischemia-reperfusion injury (IRI) in the lung is an inevitable consequence of LTx. IRI is known to promote development of primary graft dysfunction (PGD) – one of the leading causes of patient illness and death after LTx. As a result, there is a critical need for the development of therapeutic avenues to target IRI to improve patient outcome post-transplant. Necroptosis, a form of regulated cell death, has been implicated as a major promoter of IRI in studies done with cells and animals simulating LTx. However, this has not been tested in human LTx cases. We hypothesize that necroptosis plays a critical role in IRI in human LTx and will influence the clinical outcome of patients following LTx. To test this, we will assess biopsies from human donor lungs and the plasma of the recipient patients after LTx for the presence of necroptosis markers. The levels of these markers will then be assessed in relation to the characteristics of the donor patients and the clinical outcome of the recipient patients. Overall, these results will identify the clinical relevance of necroptosis in human LTx and potentially highlight a new avenue for future therapeutics that target IRI; ultimately, increasing the use of donor lungs and improving post-transplant patient outcomes.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Main, Kimberly L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~